By summarizing existing literature, conference reports, and clinical trial data, our study discusses the epidemiology of KRAS G12C Mutant NSCLC, the oncogenic mechanisms of KRAS mutations, and their immune impact. Here, KRAS is linked to non-small cell lung carcinoma.